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The addition of chemotherapy to radiotherapy (RT) following surgery in patients with low 
grade glioma prolongs survival. In the recently published long-term follow-up of a 
randomised phase 3 trial, Buckner et. al reported 254 patients with high-risk WHO 
Grade II oligodendroglioma, oligoastrocytoma, or astrocytoma, randomised to either 
receive RT alone or RT followed by 12 months of procarbazine, vincristine and 
lomustine (PCV) chemotherapy [1]. In this study, high-risk was defined as patients aged 
40 and over, or patients under 40 who had undergone subtotal resection or biopsy. 
Median follow up was 11.9 years by which time 67% had disease progression and 55% 
of patients had died. The addition of PCV to RT improved median overall survival 
(mOS) from 7.8 to 13.3 years (HR 0.59 p=0.003), and 10-year survival increased from 
40% to 60%. Survival benefit was seen in all histological subtypes, although not 
statistically significant in astrocytomas (oligodendroglioma: HR 0.43 [95% CI 0.23-0.82] 
p=0.009; oligoastrocytoma: HR 0.56 [0.32-1.00] p=0.05; astrocytoma: HR 0.73 [0.40-
1.34] p=0.31). Patients with isocitrate dehydrogenase 1 (IDH1) R132 mutation also had 
significant survival benefit from the addition of PCV (HR 0.42 [0.20-0.86] p=0.02), but 
conclusions were not made for patients with 1p19q co-deletion or with IDH wild-type 
tumours. Of note, patients who were randomised to RT alone were more likely to 
receive further treatment, but only 56% received chemotherapy, reasons for which are 
unclear. 
 
This trial adds further evidence that adjuvant chemotherapy significantly improves 
survival in glioma. The EORTC26951 trial evaluated the addition of PCV to adjuvant RT 
in 368 patients with newly diagnosed anaplastic oligodendroglioma (WHO Grade III) 
and demonstrated an improvement in mOS with the addition of PCV from 30.6 to 42.3 
months (HR 0.75 [0.60-0.95]) [2]. In the RTOG 9402 trial, mOS in patients with 
anaplastic glioma (WHO grade III) with 1p19q co-deleted tumours treated with RT plus 
PCV (n=148) was 14.7 years, compared with 7.3 years in those treated with RT (n=143) 
alone (HR 0.59 [0.37-0.95] p=0.03) [3]. Patients with IDH mutant tumours in this trial 
also derived benefit from the addition of PCV (mOS 9.4 versus 5.7 years, HR 0.59 
[0.40-0.86] p=0.006) [4]. In patients with anaplastic glioma without 1p19q co-deletion, 
interim analysis from the CATNON trial  has  shown the addition of temozolomide to 
radiotherapy improves survival, although median overall survival has not yet been 
reached (HR for OS 0.65 [0.45-0.93] p=0.0014) [5]. In these trials, survival benefit was 
not observed until approximately 25% of patients had died, possibly reflecting the 
proportion of patients with chemoresistant disease. Thereafter, survival benefit 
increased with time. 
 
Tumour biomarkers including IDH, 1p19q, and MGMT are associated with prognostic 
advantage and chemosensitivity [6, 7]. Lower grade gliomas which are IDH wild-type 
and without 1p19q co-deletions are considered morphologically and clinically similar to 
glioblastoma (WHO Grade IV) [6, 8]. RT with temozolomide chemotherapy is the 
established standard of care in glioblastoma. Universal adoption of this regimen 
followed the demonstration of a modest increase in mOS survival from 12.1 to 14.6 
months (HR 0.63 [0.52-0.75] p<0.01) with addition of temozolomide to RT in the 
EORTC/NCIC randomised trial of 573 patients [9, 10]. 
 
In current practice, patients with glioblastoma are given adjuvant chemotherapy despite 
relatively limited benefit, whilst it is not routinely given to patients with low grade glioma 
who are more likely to benefit. Given the survival benefit demonstrated in clinical trials, 
we believe that all patients with grade IV, III, and high-risk grade II glioma and good 
performance status should be offered RT and chemotherapy after surgical resection. 
The potential for late toxicity is the primary negative sequelae of earlier chemotherapy 
and should be discussed with patients prior to commencing treatment. Possible late 
side effects of cytotoxic chemotherapy include neurocognitive decline, cardiovascular 
disease, reduced fertility, fatigue, and secondary neoplasms [11-14]. 
 
Whether patients with lower grade glioma should be given RT with concomitant and 
adjuvant temozolomide (the standard in glioblastoma) or RT followed by adjuvant PCV 
remains uncertain, and is under investigation in the CODEL Phase III clinical trial 
(NCT00887146).  Future studies should aim to identify low-risk patients in whom it is 
safe to delay adjuvant therapy following surgery. Future patient stratification may occur 
with molecular signatures determined through analysis of ongoing studies of next 
generation sequencing of the tumour genome, transcriptome, and epigenome. These 
studies are aiming to establish a biomarker that is independently prognostic and 
predictive of response to therapy. 
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